Hodgkin lymphoma, named after Dr. Thomas Hodgkin, is a cancer that affects the lymphatic system which makes up part of the body’s immune system. Specifically, Hodgkin lymphoma occurs when the DNA changes in white blood cells called lymphocytes.
The survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances. Florida Cancer Specialists & Research Institute (FCS) physicians and patients are part of these leading-edge cancer innovations.
Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologists Ivor Percent, MD, Maen Hussein, MD, and Viralkumar Bhanderi, MD, contribute observations for Phase II study. Another presentation at ASCO GI 2022 includes Phase I observations from FCS physician, Manish R. Patel, MD.
A variety of drugs are used to treat cancer. Delivered by infusions, injections, or taken orally, it takes a range of specially trained professionals working together to ensure that these pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.
While everyone should aim to eat healthy, cancer survivors in particular must make healthy, selective choices when preparing a meal. It is crucial to support the body, which continues to heal post-treatment.
Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Gail Lynn Shaw Wright, MD, FACP, FCCP is co-author of a Phase II study that examined the efficacy of administering Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer.
FCS Top News Updates
FCS Contributing To Breakthroughs In Treatment of Blood Cancers & Disorders
Florida Cancer Specialists & Research Institute Announces Senior Leadership AppointmentFCS announced the newest addition to its senior management team. Joshua Eaves joined FCS as Senior Vice President Corporate Development.
Understanding Hodgkin LymphomaHodgkin lymphoma, named after Dr. Thomas Hodgkin, is a cancer that affects the lymphatic system which makes up part of the body’s immune system. Specifically, Hodgkin lymphoma occurs when the DNA changes in white blood cells called lymphocytes.
Advancing Therapies for Patients Through Clinical Research in Community Oncology PracticesThe survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances. Florida Cancer Specialists & Research Institute (FCS) physicians and patients are part of these leading-edge cancer innovations.
Florida Cancer Specialists Physician Studies Featured at American Society of Clinical Oncology 2022 Gastrointestinal Cancers SymposiumFlorida Cancer Specialists & Research Institute, LLC (FCS) medical oncologists Ivor Percent, MD, Maen Hussein, MD, and Viralkumar Bhanderi, MD, contribute observations for Phase II study. Another presentation at ASCO GI 2022 includes Phase I observations from FCS physician, Manish R. Patel, MD.
Pharmacists in the Front-Line: The Fight Against CancerA variety of drugs are used to treat cancer. Delivered by infusions, injections, or taken orally, it takes a range of specially trained professionals working together to ensure that these pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.
Jim Corsi’s Final Message Reminds Fans to Get Screened for CancerThe sports world is mourning the loss of Jim Corsi who passed away after a battle with liver and colon cancer.
Feeding Healthy Outcomes: Wellness Tips For Cancer PatientsWhile everyone should aim to eat healthy, cancer survivors in particular must make healthy, selective choices when preparing a meal. It is crucial to support the body, which continues to heal post-treatment.
Gail Lynn Wright, MD Co-Authors Phase II Study Examining Trilaciclib in Treatment of Metastatic Triple-Negative Breast CancerFlorida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Gail Lynn Shaw Wright, MD, FACP, FCCP is co-author of a Phase II study that examined the efficacy of administering Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer.